The Advanced Research Projects Agency for Health (ARPA-H) has released the Intelligent Generator of Research (IGoR) Innovative Solutions Opening (ISO), a bold initiative designed to fundamentally transform how biomedical research is conducted. Managed through ARPA-H’s Proactive Health Office, the program seeks to address longstanding inefficiencies in scientific discovery by creating an artificial intelligence (AI)-enabled interoperable research ecosystem capable of accelerating validated knowledge generation by at least 10 times over conventional approaches.
Rather than focusing on a single therapeutic target or disease mechanism, IGoR aims to establish a scalable infrastructure that continuously integrates mechanistic disease modeling, AI-driven hypothesis generation, interoperable experimental protocols, and distributed laboratory execution into a unified research cycle.
Addressing the Challenges of Modern Biomedical Research
ARPA-H frames the program around a central challenge in modern biomedical research: despite enormous advances in data generation and AI-enabled analysis, research workflows remain fragmented, difficult to reproduce, and slow to validate experimentally. According to the program documentation, IGoR is intended to eliminate these bottlenecks by building a system in which researchers can rapidly identify knowledge gaps, design experiments, execute them across qualified laboratories, and automatically integrate resulting data back into mechanistic disease models.
Importantly, the agency emphasizes that IGoR is not intended to replace scientists with automation. Instead, the platform is designed to amplify human scientific judgment by allowing researchers to pursue increasingly complex and resource-intensive questions that are currently impractical under traditional research models.
The Four Technical Areas Driving IGoR
The program is organized around four tightly integrated Technical Areas (TAs).
TA1: Comprehensive Disease Models
Technical Area 1 (TA1) focuses on the development of modular, mechanistic, multiscale disease models that function as “digital twins” capable of encoding causal biological relationships across molecular, cellular, tissue, and organ scales. These models must be verifiable, interoperable, and continuously updated with experimental data.
TA2: New Science Engine
Technical Area 2 (TA2), referred to as the “New Science Engine,” serves as the orchestration layer responsible for identifying knowledge gaps, generating hypotheses, designing experiments, and explaining AI reasoning to researchers through interpretable narratives and visualizations.
ARPA-H specifically notes that simple large language model (LLM) wrappers around laboratory automation will not satisfy program requirements; instead, the agency is seeking architectures grounded in mechanistic reasoning, multi-agent deliberation, and structured scientific debate.
TA3: Interoperable Experimental Procedures
Technical Area 3 (TA3) introduces one of the program’s most ambitious concepts: an interoperable experimental protocol architecture capable of separating scientific intent from hardware-specific execution instructions. The goal is to make experimental procedures transferable between laboratories with the same ease as digital data transfer, thereby reducing procedural variation and improving reproducibility.
TA4: Experiment Marketplace
Technical Area 4 (TA4) complements this effort by establishing a distributed “experiment marketplace” consisting of validated laboratories, including cloud labs, contract research organizations (CROs), academic facilities, and autonomous laboratory systems, that can execute standardized protocols and return high-quality data suitable for automated model ingestion.
Over the course of the five-year, three-phase program, teams will progress from intra-team closed-loop demonstrations to cross-team interoperability and ultimately to a unified experimental marketplace capable of supporting external researchers.
Program Structure and Funding Overview
ARPA-H anticipates awarding multiple Other Transaction (OT) agreements to approximately three multidisciplinary performer teams, each of which must address all four Technical Areas. The program is structured across three phases over five years:
- Phase I (18 months): Concept and component development, including initial closed-loop demonstrations within individual teams.
- Phase II (18 months): Cross-team integration and interoperability demonstrations, including shared protocol execution across laboratories.
- Phase III (24 months): Scaling, transition, commercialization planning, and extension into a second disease area.
The solicitation also includes extensive quantitative milestones and performance metrics. Among the program’s marquee goals are:
- Achieving a 10x reduction in experimental cycle time from hypothesis generation to validated experimental insight.
- Demonstrating ≥90% inter-laboratory concordance across standardized experiments.
- Enabling automated disease model updates within four hours of experimental data return.
- Establishing interoperable protocol standards and open-access repositories for computational artifacts and metadata.
Important Proposal Dates
Organizations interested in participating in the IGoR program should closely monitor the following deadlines:
- Proposers’ Day: To Be Determined (TBD)
- Solution Summaries Due: June 25, 2026 at 12:00 PM Eastern Time
- Full Proposals Due: August 6, 2026 at 12:00 PM Eastern Time (Noon)
ARPA-H notes that registration through the ARPA-H Solutions submission portal is required in advance of submissions and recommends early registration due to System for Award Management (SAM.gov) processing timelines.
A New Model for Accelerating Human Health Research
Beyond the technical requirements, IGoR represents a significant strategic investment in the future of biomedical discovery infrastructure. The program specifically targets complex diseases characterized by multifactorial causes, poorly understood mechanisms, and dynamic biological interactions, including neurodegenerative disorders, autoimmune disease, chronic pain syndromes, and emerging infectious diseases.
If successful, IGoR could dramatically shorten the time required to identify therapeutic targets, validate biological mechanisms, and generate reproducible scientific knowledge across institutions and disciplines. By combining AI-enabled reasoning, interoperable experimentation, and distributed research execution, ARPA-H aims to create a sustainable research ecosystem capable of accelerating breakthroughs in some of the most difficult areas of human health.
If your company has considered applying for federal funding, your federal funding journey starts here. EverGlade is a national firm that helps organizations win and manage federal awards. We offer services ranging from Pursuit, Proposal and Post-Award support to comply with federal regulations at agencies including BARDA, ARPA-H, NIH, DTRA, JPEO, DOD, DIU, DOE, and DARPA.
